Of those, 8 compounds (α-eudesmol, γ-eudesmol, (−)-terpinen-4-ol, terpineol, hinesol, linalool, borneol, and β-eudesmol) and 8 targets (TNF, IL-1β, PPARγ, PPARα, PTGS2, NCOA1, CNR1, and ESR1) have a close relationship with AP treatment and were recognized as the key active compounds and the core therapeutic targets, respectively. The gene discussed is PPARG; the disease is alkaline phosphatase measurement.